European Journal of Clinical Pharmacology

, Volume 5, Issue 4, pp 226–228 | Cite as

Amantadine in depression: Relationship between behavioural effects and plasma levels

  • M. Rizzo
  • P. Biandrate
  • G. Tognoni
  • P. L. Morselli
Originals

Summary

Administration of amantadine to depressed patients for 2–3 weeks induced aggressive behaviour, which disappeared when the drug was discontinued. Steady state plasma levels lay between 0.68 and 1.01 µg/ml; the apparent plasma half-life of the drug was 21 h with a Vd of 6.2 l/kg.

Key words

Amantadine plasma levels depression aggressive behaviour 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schwab, R. S., England, A. C., Jr., Poskanzer, D. C., Young, R. R.: Amantadine in the treatment of Parkinson's disease. J. Amer. med. Ass.208, 1168–1170 (1969).Google Scholar
  2. 2.
    Parkes, J. D., Calver, D. M., Zilka, K. J., Knill-Jones, R. P.: Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet1970 I, 259–262.Google Scholar
  3. 3.
    Voller, G. W.: Die Behandlung des Parkinson-Syndroms mit Amantadin. Dtsch. med. Wschr.95, 934–937 (1970).Google Scholar
  4. 4.
    Fieschi, C., Nardini, M., Casacchia, M., Tedone, M. E., Robotti, E.: Amantadine for Parkinson's disease. Lancet1970 I, 945–946.Google Scholar
  5. 5.
    Millac, P., Hasan, I., Espir, M. L. E., Slyfield, D. G.: Amantadine in Parkinson's disease. Lancet1970 I, 464.Google Scholar
  6. 6.
    Fieschi, C., Nardini, M., Casacchia, M., Tedone, M. E., Reitano, M., Robotti, E.: Amantadine versus L-Dopa and amantadine plus L-Dopa. Lancet1970 II, 154–155.Google Scholar
  7. 7.
    Venier, V. G., Harman, J. B., Stump, J. M., Lynes, T. E., Marvel, J. P., Smith, D. H.: The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicol. appl. Pharmacol.15, 642–665 (1969).Google Scholar
  8. 8.
    Fibiger, H. C., Fox, M., McGeer, E. G., McGeer, P. L.: The effect of amantadine on spontaneous locomotor activity in the rat. J. Pharm. Pharmacol.23, 724–725 (1971).Google Scholar
  9. 9.
    Zetler, G.: Anticataleptic actions of amantadine hydrochloride. Naunyn-Schmiedeberg's Arch. exp. Path. Pharmak.266, 276–278 (1970).Google Scholar
  10. 10.
    Svensson, T. H., Strömberg, U.: Potentiation by amantadine hydrochloride of L-Dopa-induced effects in mice. J. Pharm. Pharmacol.22, 639–640 (1970).Google Scholar
  11. 11.
    Svensson, T. H., Thieme, G.: An investigation of a new instrument to measure motor activity of small animals. Psychopharmacol. (Berl.)14, 157–163 (1969).Google Scholar
  12. 12.
    Fletcher, E. A., Redfern, P. H.: The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates. J. Pharm. Pharmacol.22, 957–959 (1970).Google Scholar
  13. 13.
    Scatton, B., Cheramy, A., Besson, M. J., Glowinsky, J.: Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Europ. J. Pharmacol.13, 131–133 (1970).Google Scholar
  14. 14.
    Baldessarini, R. J., Lipinski, J. F., Chance, K. V.: Effects of amantadine hydrochloride on catecholamine metabolism in the brain of the rat. Biochem. Pharmacol.21, 77–87 (1972).Google Scholar
  15. 15.
    Voitglander, P. F. von, Moore, K. E.: Dopamine: release from the brain in vivo by amantadine. Science174, 408–410 (1971).Google Scholar
  16. 16.
    Vale, S., Espejel, M. A., Dominguez, J. C.: Amantadine in depression. Lancet1971 II, 437.Google Scholar
  17. 17.
    Zeally, A. K., Aitken, R. C. B.: Measurement of mood. Proc. roy. Soc. Med.62, 993–996 (1969).Google Scholar
  18. 18.
    Overall, J. E., Gorham, D. R.: The brief psychiatric rating scale. Psychol. Rep.10, 799–812 (1962).Google Scholar
  19. 19.
    Biandrate, P., Tognoni, G., Belvedere, G., Frigerio, A., Rizzo, M., Morselli, P. L.: A new method for amantadine determination in human plasma. J. Chromatog.74, 31–34 (1972).Google Scholar
  20. 20.
    Bleinder, W. E., Harmon, J. B., Hewes, W. E., Lynes, T. E., Hermann, E. C.: Absorption, distribution and excretion of amantadine hydrochloride. J. Pharmacol. exp. Ther.150, 484–490 (1965).Google Scholar
  21. 21.
    Goodwin, F. K., Murphy, D. L., Brodie, H. K. H., Bunney, W. E., Jr.: L-Dopa, catecholamines and behavior: clinical and biochemical study in depressed patients. Biol. Psychiat.2, 341–366 (1970).Google Scholar
  22. 22.
    Goodwin, F. K., Murphy, D. L., Brodie, H. K. H., Bunney, W. E., Jr.: Levodopa: alterations in behavior. Clin. Pharmacol. Ther.12, 383–396 (1971).Google Scholar
  23. 23.
    Maj, J., Sowinska, H., Baran, L.: The effect of amantadine on motor activity and catalepsy in rats. Psychopharmacol. (Berl.)24, 296–307 (1972).Google Scholar

Copyright information

© Springer-Verlag 1973

Authors and Affiliations

  • M. Rizzo
    • 1
  • P. Biandrate
    • 1
  • G. Tognoni
    • 1
  • P. L. Morselli
    • 1
  1. 1.Istituto di Ricerche Farmacologiche “Mario Negri”MilanoItaly

Personalised recommendations